CagriSema
cagrilintide/semaglutide, cagrilintide-semaglutide
Novo's answer to tirzepatide: two of its own drugs in one pen, reaching 22.7% weight loss in phase 3 and still not approved anywhere.
Human trials
Investigational. Phase 3 REDEFINE results are published in the New England Journal of Medicine and the combination is not approved in the United States or elsewhere for weight loss.
What it is
CagriSema is cagrilintide and semaglutide co-formulated in one weekly injection. Both are Novo Nordisk molecules, and the reason for combining them is that they suppress appetite through separate pathways: semaglutide at the GLP-1 receptor, cagrilintide as a long-acting amylin analogue.
That makes it structurally different from tirzepatide and retatrutide, which are single molecules engineered to hit several receptors. CagriSema is two drugs in one pen. The commercial logic is the same, the manufacturing logic is not.
What the evidence shows
REDEFINE 1 randomised 3,417 adults with obesity or overweight plus a comorbidity, without type 2 diabetes, to CagriSema 2.4/2.4, cagrilintide alone, semaglutide alone or placebo for 68 weeks.
| Arm | Mean weight reduction |
|---|---|
| CagriSema 2.4/2.4 | 22.7% |
| Semaglutide 2.4 mg | 16.1% |
| Cagrilintide 2.4 mg | 11.8% |
| Placebo | 2.3% |
60% of the CagriSema group lost at least 20% of body weight, 40% lost at least 25%, and 23% lost 30% or more. REDEFINE 2 ran the comparison in people with type 2 diabetes, where weight loss is consistently smaller across this entire class.
Having all four arms in one trial is unusually informative. It shows the combination beating each component alone, which is the thing combination products usually assert and rarely demonstrate in the same protocol.
The number that disappointed the market
22.7% was received as a letdown, which says more about expectations than about the drug. Novo had guided toward roughly 25%, and the shortfall moved the share price hard.
In clinical terms, a weekly injection producing over 22% mean weight loss with 23% of participants past 30% is close to what bariatric surgery achieves. It is worth separating the investment story from the medical one, because the coverage of this compound conflated them thoroughly.
Practical notes
- Losing this much weight makes lean mass a real concern. At 25% or 30% total reduction, a meaningful fraction is not fat unless resistance training and protein intake are handled deliberately.
- Two mechanisms means two side effect profiles. The gastrointestinal burden in REDEFINE was greater than semaglutide alone, which is the expected cost of adding the amylin arm.
- The components exist separately and stacking them yourself is not the same thing. The trial used a co-formulated product with a defined joint titration. Combining two grey-market vials reproduces neither the formulation nor the schedule.
Side effects and warning signs
Commonly reported
- Nausea, vomiting and diarrhoea, with the amylin component adding to the incretin burden
- Constipation
- Injection-site reactions
- Gallstones, associated with the rate of weight loss
Stop and get medical help
- Personal or family history of medullary thyroid carcinoma or MEN2
- Severe persistent abdominal pain radiating to the back
- Loss of lean mass at this magnitude of weight reduction, which makes resistance training and protein intake a clinical matter rather than a preference
Sources
From the community
Discussion for this compound concentrates in r/Semaglutide and r/loseit.
No threads cached yet.
Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.